A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease

Abstract

AIMS To ascertain the tolerability profile of single and repeated oral doses of methanesulfonyl fluoride (MSF, SNX-001) in healthy aged subjects, and to determine the degree of erythrocyte acetylcholinesterase (AChE) inhibition induced by MSF after single and repeated oral doses. METHODS To calculate properly the kinetics and the duration of AChE… (More)
DOI: 10.1111/bcp.12018

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Moss2013ARP, title={A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease}, author={Donald E Moss and Ruggero G. Fariello and J{\"{o}rg Sahlmann and Isabel C. Sumaya and Federica Pericle and Enrico Braglia}, booktitle={British journal of clinical pharmacology}, year={2013} }